TY - JOUR
T1 - Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models
AU - Baker, K.E.
AU - Bonvini, S.J.
AU - Donovan, C.
AU - Foong, Rachel
AU - Han, B.
AU - Jha, A.
AU - Shaifta, Y.
AU - Smit, M.
AU - Johnson, J.R.
AU - Moir, L.M.
PY - 2014/12
Y1 - 2014/12
N2 - Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent respiratory diseases characterized by airway inflammation, airway obstruction and airway hyperresponsiveness. Whilst current therapies, such as β-agonists and glucocorticoids, may be effective at reducing symptoms, they do not reduce disease progression. Thus, there is a need to identify new therapeutic targets. In this review, we summarize the potential of novel targets or tools, including anti-inflammatories, phosphodiesterase inhibitors, kinase inhibitors, transient receptor potential channels, vitamin D and protease inhibitors, for the treatment of asthma and COPD.
AB - Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent respiratory diseases characterized by airway inflammation, airway obstruction and airway hyperresponsiveness. Whilst current therapies, such as β-agonists and glucocorticoids, may be effective at reducing symptoms, they do not reduce disease progression. Thus, there is a need to identify new therapeutic targets. In this review, we summarize the potential of novel targets or tools, including anti-inflammatories, phosphodiesterase inhibitors, kinase inhibitors, transient receptor potential channels, vitamin D and protease inhibitors, for the treatment of asthma and COPD.
U2 - 10.1016/j.pupt.2014.05.008
DO - 10.1016/j.pupt.2014.05.008
M3 - Article
SN - 1094-5539
VL - 29
SP - 181
EP - 198
JO - Pulmonary Pharmacology and Therapeutics
JF - Pulmonary Pharmacology and Therapeutics
IS - 2
ER -